Mesoblast Ltd
MESO10.160USD
-0.275-2.64%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
1.17BMarket Cap
LossP/E TTM
More Details of Mesoblast Ltd Company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Company Info
Ticker SymbolMESO
Company nameMesoblast Ltd
IPO dateDec 16, 2004
Founded at2004
CEODr. Silviu Itescu
Number of employees73
Security typeDepository Receipt
Fiscal year-endDec 16
AddressL 38 55 Collins St
CityMELBOURNE
Stock exchangeNASDAQ Global Select Consolidated
CountryAustralia
Postal code3000
Phone61396396036
Websitehttps://www.mesoblast.com/
Ticker SymbolMESO
IPO dateDec 16, 2004
Founded at2004
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
41.16K
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
41.16K
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
0.44%
Citadel Advisors LLC
0.38%
Morgan Stanley & Co. International Plc
0.25%
Susquehanna International Group, LLP
0.20%
Goldman Sachs & Company, Inc.
0.20%
Other
98.52%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
0.44%
Citadel Advisors LLC
0.38%
Morgan Stanley & Co. International Plc
0.25%
Susquehanna International Group, LLP
0.20%
Goldman Sachs & Company, Inc.
0.20%
Other
98.52%
Shareholder Types
Shareholders
Proportion
Investment Advisor
1.46%
Research Firm
0.99%
Hedge Fund
0.45%
Investment Advisor/Hedge Fund
0.20%
Individual Investor
0.06%
Other
96.83%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
121
3.21M
2.52%
-64.68K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
2023Q2
99
982.29K
1.21%
-1.15M
2023Q1
103
1.33M
1.81%
-837.80K
2022Q4
108
1.43M
1.94%
-964.96K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
584.29K
0.46%
+584.29K
--
Dec 31, 2024
Morgan Stanley & Co. International Plc
163.50K
0.13%
+163.50K
--
Dec 31, 2024
Susquehanna International Group, LLP
153.98K
0.12%
+37.24K
+31.90%
Dec 31, 2024
Morgan Stanley & Co. LLC
225.25K
0.18%
+54.27K
+31.74%
Dec 31, 2024
Summit Wealth Strategies
145.66K
0.11%
-2.04K
-1.38%
Dec 31, 2024
UBS Financial Services, Inc.
165.15K
0.13%
+165.15K
--
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
iShares Biotechnology ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
ActivePassive International Equity ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Date
Type
Ratio
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
Dec 22, 2023
Merger
2<1
